Mont-Saint-Guibert, Belgium, February 12, 2026, 7:00am CET, Regulated Information / Inside Information – Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced the acquisition by CellProthera of C-Cathez®, the transendocardial catheter originally developed by Celyad Oncology. The acquisition is a decisive step for CellProthera as it prepares to enter Phase 3 clinical trial, with the transendocardial catheter as a cornerstone of its therapeutic approach, enabling targeted delivery of stem cells directly into damaged cardiac tissue. The transaction relates to all intellectual property rights and associated technical documentation.
Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million payable in instalments tied to milestones, and (ii) future royalties on net sales.
The consideration being entirely deferred, the transaction will not impact Celyad Oncology’s current cash runway, which is currently anticipated to extend into Q3-2026
